Source link : https://www.newshealth.biz/health-news/glp-1s-boost-ibd-outcomes-in-patients-with-t2d-and-obesity/
TOPLINE: The use of glucagon-like peptide 1 (GLP-1) receptor agonists is associated with a reduced risk for poor inflammatory bowel disease (IBD)–related outcomes in patients with both IBD and type 2 diabetes (T2D), specifically in those with obesity. METHODOLOGY: The growing use of GLP-1s for T2D and obesity necessitates a better understanding of their effect […]
Author : News Health
Publish date : 2024-12-06 10:04:30
Copyright for syndicated content belongs to the linked Source.